

L.A. Care Health Plan's CME and CE Activities Ground Rules





Welcome, Thank you for being here today and Thank you to Presenter(s) and L.A. Care Staff



L.A. Care Provider Continuing Education (PCE) Program

CME & CE Activities' Ground Rules



- ALL phones must be on silent mode.
- Partial credits are not allowed for those who come in late or leave early. Dinner Events and Saturday Conferences and PCE Program webinars are CME/CE activities and L.A. Care must stay in compliance with our accreditation Boards (CMA, CA BRN and CAMFT).
- Please refrain from having conversations at your table while the presentation is going on. Let's all be mindful and respectful to our presenters and to each other.
- For Q&A session, please keep your questions brief, concise and to the point.
- Respect others opinions; Agree to disagree.
- Powerpoint presentations will not be emailed.
 Please take notes.
- End of the Program is End of Closing Remarks by our Host(s) for Saturday Conferences and/or end of Q&A session by presenter for CME/CE dinner events.
- Please complete the evaluation form at the end of the program and submit to L.A. Care staff at the registration table in exchange for the CME / CE certificate.
- Each attendee / learner is responsible for keeping track of their own CME or CE credits and certificates. The L.A. Care PCE Program Manager is not responsible for looking up which Conferences and dinner events you attended in the past. The L.A. Care PCE Program Manager can only verify your attendance based on the sign in sheets if you provide the dates of the Conferences and webinars you attended.
- L.A. Care has limited budget for our CME/CE activities, therefore, limited with what we can provide for breakfast, lunch, afternoon snack and/or dinner.

Thank you for your understanding and cooperation!

Presenter's Bio

Sande Okelo, MD, PhD

- As a pediatric pulmonologist and researcher, Dr. Okelo is interested in improving asthma care for children, particularly those children at risk for poor care and poor asthma outcomes. He has developed an asthma specialist clinic for children that incorporates clinical care, patient education and clinical research. Dr. Okelo's research interests range from physician decision-making regarding asthma treatment to the development of strategies to improve asthma care.
- Associate Professor of Pediatrics, UCLA
- Director, Pediatric Asthma Center of Excellence, UCLA



Asthma Management in the Primary Care Setting

April 25, 2024, Almansor Court, Alhambra, CA 91801 CME/CE Dinner Event, 6:30 pm – 8:30 pm PST, 2 CME/CE Credits Directly Provided CME / CE Activity by L.A. Care Health Plan

Sande Okelo, MD, PhD

UCLA Division of Pediatric Pulmonology and Sleep Medicine



Disclosures

The following CME planners and faculty do not have relevant financial relationships with ineligible companies in the past 24 months:

- Leilanie Mercurio, L.A. Care PCE Program Manager, CME Planner
- Sande Okelo, MD, PhD, Associate Professor of Pediatrics, UCLA;
 Director, UCLA Pediatric Asthma Center of Excellence, CME Planner and Faculty

An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Commercial support was not received for this CME/CE activity.



Cultural and Linguistic Competency (CLC)

This presentation includes content or topics that address:

- Patient Demographics including Age, Race/Ethnicity, Gender, Sexual Orientation
- Language/ Communication
- Religion
- Socioeconomics
- Physical Abilities / Qualities
- Awareness and Attitude Towards Cultural Differences
- Health Literacy
- Disparities in Care, Education, Geographic Location

Course Outline

- 1. Asthma diagnosis
- 2. Asthma assessment questionnaire in asthma management
- 3. 2020 Asthma Guideline Updates: intermittent inhaled steroids and SMART therapy
- 4. Case-based learning

Learning Objectives

- 1. List the three (3) asthma diagnostic criteria from national asthma guidelines.
- 2. Summarize how to incorporate an asthma assessment questionnaire into clinical practice.
- 3. Identify the four (4) levels of asthma severity (intermittent, mild persistent, moderate persistent, severe persistent) using an asthma assessment questionnaire.
- 4. Summarize the differential diagnosis of uncontrolled asthma.

A few thoughts before we start...

- 1. Asthma is simple but not easy
- 2. When not diagnosing or not treating asthma, are you doing harm?
 - 1. How do you know?
- 3. Your asthma care should be a results-driven process
 - Is your patient doing well or not?
 - 1. How do you know?
- 4. No standardization of assessment = poor care

Case

- 26 month old male presenting to ER w/ one day of cough, post-tussive emesis, fatigue, and respiratory distress including retractions and increased work of breathing.
- Dx'd with bronchiolitis ~3wks ago: symptom-relief with albuterol inhaler; used ~twice in the last three weeks for evening/night time cough. Family declined prednisone.
- Dad w/ asthma. Mom/Dad w/ seasonal allergies
- ED Course: Pulse140|Temp 36.1| Resp 44 | SpO2 (!) 85%
- Mod resp distress: tachypnea, accessory muscle use, exp wheeze.
- Duoneb x2, zofran x1, NS 30mL/kg x1, methylpred 1mg/kg x1
- CXR reassuring against focal consolidation.
- Improved exam, but cont'd wheezing and poor air movement



Hospital Course

- Hosp x 3 days.
- Continuous albuterol. Methylprednisolone. Desaturated 91% when continuous albuterol removed, 2L NC initiated.
- Wheezing resolved and air movement throughout lungs significantly improved.
- ADMISSION DIAGNOSES: Viral illness, bronchiolitis
- DISCHARGE DIAGNOSES: Viral illness, reactive airway disease

Discharge: Dosing & Instructions

Medication List

What's missing?

START taking these medications

acetaminophen 32 mg/ml liquid

Commonly known as: Tylenol

Take 3.5 mLs (112 mg total) by mouth every six (6) hours as needed.

dexamethasone 2 mg tablet

Take 3 tablets (6 mg total) by mouth once Please crush, mix in food, and give 10/7 at night for 1 dose.

CONTINUE taking these medications

albuterol 90 mcg/act inhaler

Commonly known as: Proventil HFA, Ventolin HFA

Inhale 2 puffs every four (4) hours as needed (shortness of breath or wheezing).



NIH Asthma Guidelines: Expert Panel Reports: Systematic Review of Evidence + Expert Opinion






GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION

Updated 2021

GINA Asthma Guidelines 2021

CONTROL-BASED ASTHMA MANAGEMENT


In control-based asthma management, pharmacological and non-pharmacological treatment is adjusted in a continuous cycle that involves assessment, treatment and review (Box 3-2). Asthma outcomes have been shown to improve after the introduction of control-based guidelines or practical tools for implementation of control-based management strategies. The concept of control-based management is also supported by the design of most randomized controlled medication trials, with patients identified for a change in asthma treatment on the basis of features of poor symptom control with or without other risk factors such as low lung function or a history of exacerbations.




Diagnosis



Biology of Asthma



Asthma Pathogenesis




To establish a diagnosis of asthma, determine that:

- Asthma symptoms occur more than once
 - Cough
 - Wheeze
 - Chest pain/tightness
 - Shortness of breath (exertional)
 - Decreased stamina
- Asthma symptoms improve with asthma medicines
 - Adequate dose, duration and echnique
- Alternative diagnoses are excluded
 - Habit cough; chronic sinusitis; GERD



How Long Are Resp Sx's in 90% of Children?



M Thompson et al. BMJ 2013; Dec;347:

Chronic Cough Definition

Coughing >4 weeks

- Avoid missing serious diagnoses
 - Foreign body aspiration
 - Immunodeficiency
 - Cystic fibrosis

Causes of Chronic Cough

- Asthma
- Aspiration
- Bronchiectasis
- Cilia dysfunction
- Congenital lung malformation
- ACE inhibitors
- Cystic Fibrosis
- Heart Failure

- GERD
- Habit Cough
- Immunodeficiency
- Post-viral Infection
- Interstitial Lung Disease
- Neuromuscular Disease
- Protracted bacterial bronchitis (PBB)
- Sinusitis (chronic)

Common Causes of Cough

- Asthma
- Aspiration
- Bronchiectasis
- Cilia dysfunction
- Congenital lung malformation
- ACE inhibitors
- Cystic Fibrosis
- Heart Failure

- GERD
- Habit Cough
- Immunodeficiency
- Post-viral Infection
- Interstitial Lung Disease
- Neuromuscular Disease
- Pertussis
- Protracted bacterial bronchitis (PBB)
- Sinusitis (chronic)

Uncommon Causes of Cough

- Asthma
- Aspiration
- Bronchiectasis
- Cilia dysfunction
- Congenital lung malformation
- ACE inhibitors
- Cystic Fibrosis
- Heart Failure

- GERD
- Habit Cough
- Immunodeficiency
- Post-viral Infection
- Interstitial Lung Disease
- Neuromuscular Disease
- Pertussis
- Protracted bacterial bronchitis (PBB)
- Sinusitis (chronic)

Rare Causes of Cough

- Asthma
- Aspiration
- Bronchiectasis
- Cilia dysfunction
- Congenital lung malformation
- ACE inhibitors
- Cystic Fibrosis
- Heart Failure

- GERD
- Habit Cough
- Immunodeficiency
- Post-viral Infection
- Interstitial Lung Disease
- Neuromuscular Disease
- Pertussis
- Protracted bacterial bronchitis (PBB)
- Sinusitis (chronic)

Case

- 26 month old male presenting to ER w/ one day of cough, post-tussive emesis, fatigue, and respiratory distress including retractions and increased work of breathing.
- Dx'd with bronchiolitis ~3wks ago: symptom-relief with albuterol inhaler; used ~twice in the last three weeks for evening/night time cough. Family declined prednisone.
- Dad w/ asthma. Mom/Dad w/ seasonal allergies
- ED Course: Pulse140 Temp 36.1 Resp 44 | SpO2 (!) 85%
- Mod resp distress: tachypnea, accessory muscle use, exp wheeze.
- Duoneb x2, zofran x1, NS 30mL/kg x1, methylpred 1mg/kg x1
- CXR reassuring against focal consolidation.
- Improved exam, but cont'd wheezing and poor air movement

Hospital Course

- Hosp x 3 days.
- Continuous albuterol. Methylprednisolone. Desaturated 91% when continuous albuterol removed, 2L NC initiated.
- Wheezing resolved and air movement throughout lungs significantly improved.
- ADMISSION DIAGNOSES: Viral illness, bronchiolitis
- DISCHARGE DIAGNOSES: Viral illness, reactive airway disease

Discharge: Dosing & Instructions

Medication List

What's missing?

START taking these medications

acetaminophen 32 mg/ml liquid

Commonly known as: Tylenol

Take 3.5 mLs (112 mg total) by mouth every six (6) hours as needed.

dexamethasone 2 mg tablet

Take 3 tablets (6 mg total) by mouth once Please crush, mix in food, and give 10/7 at night for 1 dose.


CONTINUE taking these medications

albuterol 90 mcg/act inhaler

Commonly known as: Proventil HFA, Ventolin HFA

Inhale 2 puffs every four (4) hours as needed (shortness of breath or wheezing).





EPIDEMIOLOGY


• Lowest attack rate adults (17%)

• Highest attack previously uninfected daycare infants (98%)

• Almost all children in a high-pop. urban setting will acquire by age 2 yrs.


Average Age-Specific Rates of Hospitalization for RSV Infection Among Children <24 Months of Age (2000 – 2005)

Hosp Rates for RSV




CB Hall Pediatrics Aug 2013; 132 (2) e341

Rates of RSV Hospitalizations by Age (per 1,000 persons)




N Halasa Vaccine 33 (2015):6479 - 87

Percentage of Hospitalizations for Bronchiolitis by Age, 2000 - 2009 (n = 544, 828)



Kohei Hasegawa et al. Pediatrics 2013;132:28-36

Frequency of bronchiolitis cases according to age of diagnosis (3-year cohort = 93, 058 infants).



Course Outline

1. Asthma diagnosis

2. Asthma assessment questionnaire in asthma management

3. 2020 Asthma Guideline Updates: intermittent inhaled steroids and SMART therapy

4. Case-based learning


Who? most poor outcomes in the past

How? most frequent follow-up most specialist referrals most intensive medications

Pediatric Asthma Control and **Communication** Instrument

	irection, Bother, Risk, Adherence, Conti	rol
	Communicate with Your Child's Doctor about His / Her Asthma Asthma also includes reactive airway disease, regular coughing, wheezing, or difficulty breathing with or without colds.	Risk-stratify
	Your child's name: Today's Date:	<u>- </u>
	When was your child's last asthma visit? If your child has never had an asthma visit, check here:	Identify
	Please check 🔟 one answer for each of the following questions. Your answers will help your doctor give you the best asthma care.	those with
	Questions 1-6 ask about how your child's asthma has been over the past 12 months, not just today. If your child has had asthma for less than 12 months, then think about how things have been since he/she	
	started having breathing problems. Over the past 12 months Direction	the highest
	How has your child's asthma been? Getting Staying Getting Better the Same Worse	
		risk for poor
	Over the past 12 months 2. How much have you been bothered by Not Somewhat Very	outcomes in
	your child's asthma? Bothered Bothered Bothered	
		the future
	Over the past 12 months Risk Before today: 0 1 2 3 ≥4	46 0 1110 1104
	3. How many times has your child been to	the worst
	months?	prognosis
	How many times has your child been to the emergency room for asthma over the past 12 months?	
	5. How many times has your child been hospitalized for asthma over the past 12 months?	and/or the
	6. How many times has your child used <u>an</u> oral steroid (Oranged, steroid pill, steroid	most needs
	liquid or steroid syrup) for asthma over the past 12 months? Don't include today.	
	FOR CLINICIAN USE ONLY: Partly Mildly Moderately Severely Assign patient's level of chronic asthma control by Controlled Controlled Uncontrolled Uncontrolled Uncontrolled Uncontrolled	Why?
าร	looking at the box checked farthest to the right on questions 3-6. Match the box color to the level of asthma	Limited
IJ	Take Medicine	Limiteu
	 How often do you give your My child is All of Most of Some of child's <u>daily</u> asthma medicine not supposed the time the time the time 	resources
	when he/she feels fine? to take a daily 5-7 3-4 1-2 None of Daily a sthma medicines include: a sthma days/week days/week days/week the time	1000011000111
	Advair, Alvesco, Asmanex, medicine Budesonide, Flovent, QVAR,	money,
	Pulmictort, Singular, Symbicort	cnocialists
	FOR CLINICIAN USE: If any of the answers in red are selected, this may be consistent with poorly controlled and/or undertreated asthma. Further assessment and follow-up in 2-6 weeks is recommended.	specialists,
(Clinic Urgent Care FD Hospital	etc

Clinic, Urgent Care, ED, Hospital



Pediatric Asthma Control & Communication Instrument Asthma Symptoms 7. Over the **past week**, how many days Days has your child had asthma symptoms? For example: 1-2 Every day Every day (not all day long) (all day long) · Cough · Chest tightness · Shortness of X breath • Sputum (spit, mucous, phlegm when coughing) • Difficulty taking a deep breath Wheezv or whistling sound in the chest Reliever use 8. Over the past week, how many days Days have you had to give your child medicine to quickly relieve asthma 1-2 Every day Every day symptoms? For example: (not all day long) (all day long) Albuterol - Inhaler - Spray • Pump Machine • Nebulizer Attacks 9. Over the past week, how many days did Days your child have an asthma attack? For example: • When it is harder for your child to breathe When you give your child more asthma medicine When the asthma medicine does not work **Activity Limitation** 10. Over the **past week**, how much has Not Very asthma limited your child's activities? at all Slightly Moderately much Completely Nighttime Symptoms 11. Now for this question, please answer Nights about the past 2 weeks. How many nights did your child's asthma keep your child from sleeping or wake him/her up in the past 2 weeks? For clinician use only - Asthma Control Assignment Mild Mild Moderate Assign patient's current level of asthma control by looking at box intermittent persistent persistent persistent checked farthest to the right on questions 7-11 and match color of this box to level of asthma control in this section and circle and/or document in patient's chart Controlled Not Controlled

Patient and/or Parent Completes in Waiting/Exam Room

Complete at every encounter

Clinic, Urgent Care, ED, Hospital


Enlist team members to use systematically

Lack of use risks inaccurate estimation of asthma control/ severity

If unable to use, consider lower threshold for specialist referral


Use to drive care

When to start Rescue Medication?



Follow-up in 2-6 wks to confirm asthma is controlled


When to Follow-up?



Follow-up in 2-6 wks to confirm asthma is controlled


Follow-up in 2 – 3 months to confirm asthma remains controlled

When to start Daily Controller Medications?




Follow-up in 2-6 wks to confirm asthma is controlled

When to start oral steroids?



Follow-up in 2-6 wks to confirm asthma is controlled


When to step-down or stop treatment?



When controlled for >=3 months

When controlled for >=12 months if hospitalized and/or required oral steroids


When to refer to asthma specialist?



Albuterol Inhalation for Exacerbations

		Dosages	
Medication	Child Dose (<12 yrs)	Adult Dose*(≥12 yrs)	Comments
Inhaled Short-Acting Beta	a ₂ -Agonists (SABA)		
Albuterol			
Nebulizer solution A. (0.63 mg/3 mL, 1.25 mg/3 mL, 2.5 mg/3 mL, 5.0 mg/mL)	0.15 mg/kg (minimum dose 2.5 mg) every 20 minutes for 3 doses then 0.15–0.3 mg/kg up to 10 mg every 1–4 hours as needed, or 0.5 mg/kg/hour by continuous nebulization.	2.5–5 mg every 20 minutes for 3 doses, then 2.5–10 mg every 1–4 hours as needed, or 10–15 mg/hour continuously.	Only selective beta ₂ -agonists are recommended. For optimal delivery, dilute aerosols to minimum of 3 mL at gas flow of 6–8 L/min. Use large volume nebulizers for continuous administration. May mix with ipratropium nebulizer solution.
MDI B. (90 mcg/puff)	4–8 puffs every 20 minutes for 3 doses, then every 1–4 hours inhalation maneuver as needed. Use VHC; add mask in children <4 years.	4–8 puffs every 20 minutes up to 4 hours, then every 1–4 hours as needed.	In mild-to-moderate exacerbations, MDI plus VHC is as effective as nebulized therapy with appropriate administration technique and coaching by trained personnel.


Anti-cholinergic β2 agonist: multiple doses most effective in mod – severe + exacerbations: admits





Early Oral Steroid Administration Reduces Admit Rates





Time (minutes) from triage to administration of systemic corticosteroid

Oral Steroids for Moderate/Severe Persistent Asthma 1mg/kg/day x3 – 10 days with Albuterol

Prednisolone (15mg/5ml)


Prednisolone (15mg/5ml)

OraPred (15mg/5ml)











Inhaled Steroids Reduce Death from Asthma



21% lower death rate/ each ICS cannister

50% lower death rate if used ≥6 ICS cannisters

Albuterol Use and Death from Asthma



Refills of Albuterol Inhalers in Prior Year

Used every day Treat Inflammation so used daily for ≥3 months - years 2 puffs



relax tight muscles

national nonprofit organization conditions through outreach, advocacy and research



2 times a day ProAir ProAir® RespiClick®

























INHALED CORTICOSTEROIDS reduce and prevent swelling













Asmanex[®] Twisthaler 110, 220 mcg mometasone furoate inhalation

powder

11213 A







Flovent® HFA 44, 110, 220 mcg fluticasone propionate 123 A









COMBINATION MEDICATIONS

Advair Diskus® 100/50, 250/50,

500/50 mcg fluticasone propionate and salmetero inhalation powder















0





Symbicort® 80/4.5, 160/4.5 mcg budesonide and formoterol fumarate 123 AC



Wixela™ Inhub" 100/50, 250/50, 500/50 mcg fluticasone propionate and salmeterol xinafoate 123 AC



ontain both long-acting beta₂-agonist (LABA) and long-acting muscarinic antagonist (LAMA) Anoro® Ellipta®

62.5/25 mcg umeclidinium and vilanterol inhalation










Stiolto"

Utibron™ Neohaler®

27.5/15.6 mcg indacaterol and glycopyrrolate inhalation powder





Trelegy® Ellipta® 100/62.5/25 mcg fluticasone furoate umeclidinium and vilanterol inhalation





TACONIST (AN

Incruse® Ellipta® 62.5 mca

ipratropium bromide 123





Seebri™ Neohaler® alvcopyrrolate inhalation powder



Spiriva® HandiHaler® tiotronium bromide inhalation









Combivent[®] Respimat®





BIOLOGICS target cells and pathways that cause airway inflammation; delivered by injection or IV







123



Nucala® mepolizumab



omalizuma

Xolair®



BRONCHIAL THERMOPLASTY

A minimally invasive procedure that uses mild heat to reduce airway smooth muscle, leading to fewer severe asthma flares, ER visits. and days lost from activities. www.htforasthma.com



PDE4 INHIBITORS

Daliresp® 250, 500 mcg roflumilast



123

Allergy Respiratory Treatments Allergy Respiratory Treatments Allergy Respiratory Treatments Allergy Respiratory Treatments Disease states: © = ASTHMA © = COPD





Neohaler"

inhalation powder

powder

75 mca

indacaterol

Allergy & Asthma Network is a national nonprofit organization dedicated to ending needless death and suffering due to LONG-ACTING BETA2-AGONIST BRONCHODILATORS relax tight muscles asthma, allergies and related conditions through outreach,



SHORT-ACTING BETA₂-AGONIST BRONCHODILATORS relax tight muscles in airways and offer quick relief of symptoms such as coughing, wheezing and shortness of breath for 3-6 hours

ProAir® ProAir® **HFA** Digihaler" 100 mca 117 mcg albuterol albuterol sulfate

RespiClick® 117 mcg albuterol sulfate inhalation powder 123 A

albuterol sulfate 123 0

HFA 90 mcg albuterol sulfate 123 00

Xopenex HFA® 59 mcg levalbuterol tartrate A G

in airways and offer lasting relief of symptoms such as coughing, wheezing and shortness of breath for at least 12 hours

Diskus® 50 mcg salmeteral vinafoate inhalation powde 11213 A C

Striverdi® Respimat® 2.5 mcg olodaterol hydrochloride 123 **C**



INHALED CORTICOSTEROID 3 reduce and pro-

123

Alvesco® **HFA** 80, 160 mcg ciclesonide 123 A

1|2|3 A













Asmanex® Twisthaler® 110, 220 mcg mometasone furoate inhalation powder 11213 A









inhalation

powder





ihaler"

COMBINATION MEDICATIONS

Advair Diskus® 100/50, 250/50,

500/50 mcg fluticasone propionate and salmeterol inhalation powder







AirDuo™

RespiClick®



vilanterol inhalation powder 123 OO



Dulera®

100/5, 200/5 mcg

and formoterol

mometasone furoate

Symbicort® 80/4.5, 160/4.5 mcg budesonide and formoterol fumarate





Wixela™ Inhub" 100/50, 250/50, 500/50 mcg fluticasone propionate and salmeterol xinafoate





ontain both long-acting beta₂-agonist (LABA) nd long-acting muscarinic antagonist (LAMA) Anoro® Ellipta® Bevespi

Aerosphere® 62.5/25 mcg umeclidinium and 9/4.8 mcg vilanterol inhalation glycopyrrolate and formateral fumarate





Stiolto™ Respimat® 2.5/2.5 mcg tiotropium

and olodatero



Utibron™ Neohaler® Trelegy® Ellipta® 27.5/15.6 mcg 100/62.5/25 mcg fluticasone furoate indacaterol and glycopyrrolate

umeclidinium and vilanterol inhalation powder





MUSCARINIC ANTAGONIST (ANTICHOLINERGIC)

ipratropium bromide 123









Spiriva® HandiHaler® tiotronium bromide







Tudorza™ Pressair" 400 mcg aclidinium bromide inhalation powder 123 (



COMBINATION

Combivent[®] Respimat®

ipratropium bromide and albutero



BIOLOGICS target cells and pathways that cause airway inflammation; delivered by injection or IV

123

Cingair® reslizumab













A minimally invasive procedure that uses mild heat to reduce airway smooth muscle, leading to fewer severe asthma flares, ER visits. and days lost from activities. www.btforasthma.com



PDE4 INHIBITORS


123

Daliresp® 250, 500 mcg roflumilast



Learning Objectives

- 1. Asthma diagnosis
- 2. Asthma assessment questionnaire in asthma management
- 3. 2020 Asthma Guideline Updates: intermittent inhaled steroids and SMART therapy
- 4. Case-based learning



Organization and Topics

- 6 Sections (19 Questions; 14 Recommendations)
 - Use of Exhaled Nitric Oxide in Diagnosis and Mgmt of Asthma
 - a. 5 Questions; 4 Recommendations
 - 2. Indoor Allergen Mitigation in Mgmt of Asthma
 - a. 1 Question; 4 Recommendations
 - 3. Use of Intermittent Inhaled Steroids (ICS) in the Treatment of Asthma
 - a. 3 Questions; 5 Recommendations
 - 4. Use of Long-Acting Muscarinic Antagonists for Asthma
 - a. 3 Questions; 3 Recommendations
 - 5. Subcut. and Sublingual Immunotherapy in the Tx of Allergic Asthma
 - a. 2 Questions; 2 Recommendations
 - 6. Use of Bronchial Thermoplasty to Improve Asthma Outcomes
 - a. 1 Question; 1 Recommendation



Organization and Topics

- 6 Sections (19 Questions; 14 Recommendations)
 - Use of Exhaled Nitric Oxide in Diagnosis and Mgmt of Asthma
 - a. 5 Questions; 4 Recommendations
 - 2. Indoor Allergen Mitigation in Mgmt of Asthma
 - a. 1 Question; 4 Recommendations
 - 3. Use of Intermittent ICS in the Treatment of Asthma
 - a. 3 Questions; 5 Recommendations
 - 4. Use of Long-Acting Muscarinic Antagonists for Asthma
 - a. 3 Questions; 3 Recommendations
 - 5. Subcut. and Sublingual Immunotherapy in the Tx of Allergic Asthma
 - a. 2 Questions; 2 Recommendations
 - 6. Use of Bronchial Thermoplasty to Improve Asthma Outcomes
 - a. 1 Question; 1 Recommendation



Intermittent ICS in Asthma

- 1. What is the comparative effectiveness of intermittent ICS for recurrent wheezing in children 0 − 4 years old?
- 2. What is the comparative effectiveness of intermittent ICS in patients 5 years of age and older with mild persistent asthma?
- 3. What is the comparative effectiveness of ICS-LABA (formoterol) combination therapy as both maintenance and rescue therapy in patients 5 years of age and older with persistent asthma?

- 1. What is the effectiveness of <u>intermittent ICS</u> for <u>recurrent</u> wheezing in children 0 4 years old?
 - Recurrent Wheezing
 - 3+ lifetime episodes or 2+ episodes in the past year
 - Budesonide (1mg neb BID) + QID Albuterol OR
 - Fluticasone (750mcg BID) + QID Albuterol
 - x 7 10 days

- 2. What is the effectiveness of <u>intermittent ICS</u> in patients 5+ years old with <u>mild persistent</u> asthma?
- Not Recommended for Patients <12 Years Old
- For patients 12+ years old, not on a daily inhaled steroid
 - QVAR 40: 2 6 puffs q4 hours + Albuterol 2 4 puffs q4 hours
 - •QVAR 80: 1 3 puffs q4 hours + Albuterol 2 4 puffs q4 hours
- No doubling, quadrupling or quintupling of daily inhaled steroid as needed

- 3. What is the effectiveness of ICS-LABA (formoterol) as both maintenance and rescue therapy in patients 5+ years old with persistent asthma?
- For patients with moderate-severe persistent asthma
- ICS-LABA = ICS-formoterol ONLY
 - Mometasone-Formoterol (Dulera): 100/5; 200/5
 - Budesonide-Formoterol (Symbicort): 80/4.5; 160/4.5
- One medicine for $\underline{\mathbf{M}}$ aintenance and $\underline{\mathbf{R}}$ escue $\underline{\mathbf{T}}$ reatment = $\underline{\mathbf{M}}$
 - Single inhaler for Maintenance and Rescue Treatment = \mathbf{SMART}



Allergy Respiratory Treatments













Allergy & Asthma Network is a national nonprofit organization asthma, allergies and related conditions through outreach, education, advocacy and research.

















123 A







30 30





Wixela™ Inhub" 100/50, 250/50, 500/50 mcg fluticasone propionate and salmeterol xinafoate



ontain both long-acting beta₂-agonist (LABA) and long-acting muscarinic antagonist (LAMA) Anoro® Ellipta® 62.5/25 mcg

Aerosphere® umeclidinium and 9/4.8 mcg vilanterol inhalation glycopyrrolate and formateral fumerate 123



Bevespi

Stiolto™ Respimat® 2.5/2.5 mcg tiotropium

and olodatero 123 C



Utibron™

Neohaler®

27.5/15.6 mcg

Trelegy® Ellipta® 100/62.5/25 mcg fluticasone furoate umeclidinium and vilanterol inhalation





Symbicort 80



Symbicort 160









PDE4 INHIBITORS Daliresp® 250, 500 mcg roflumilast





SMART (Single Maintenance and Rescue Therapy)

• Maintenance = 1 - 2 puffs qD - BID



• Rescue = 1 - 2 puffs BID - TID

- Total Puffs/Day: varies by age:
 - •4 11 years old: 8 puffs/day total (maintenance + rescue)
 - 12+ years old: 12 puffs/day total (maintenance + rescue)

Discovery & Innovation Institute

SMART Therapy: "Puff" Math

Age	Day	Puffs/ Day	Day (prn)	Maintenance + Rescue
4 – 11 Years	8	1puff qD	2puffs TID	2puffs TID – QID
4 – 11 Years	8	2puffs qD	2puffs TID	2puffs QID
4 – 11	8	2puffs BID	2puffs BID	2puffs QID

3puffs TID

3puffs TID

2puffs TID

3puffs **QID** or 4 puffs **TID**

3puffs QID or 4 puffs TID

3puffs QID or 4 puffs TID

65

Total Puffs/ Maintenance Rescue Puffs/ Final Regimen =

1puff qD

2puff qD

2puff BID

12

12

12

Years

12+

12+

12+

Years

Years

Years

Limitations of SMART Strategy

Insurance formularies may not cover ICS-formoterol preparations

- Patient will likely need to always have 2 inhalers
 - 120 actuations/inhaler
 - 4 puffs/day → 30 days of use
 - •8 puffs/day → 15 days of use
 - •12 puffs/day → 10 days of use
 - Mail order?
- May need to pursue "traditional" treatment
 - ICS-salmeterol + as needed albuterol/xopenex



Summary of 2020 NIH Asthma Guidelines Updates

Age Intermittent Asthma Regimen Notes

<i>7</i> (90	(ICS)?	Туре		
0 – 4 Years	Yes	Viral-induced asthma	Budesonide 1mg neb BID + QID Albuterol	x7 – 10 days ↓growth w/

Fluticasone

QVAR 40 q4 hours

QVAR 80 q4 hours

or 4puffs TID

750mcg BID + QID Albuterol

2 – 6 puff + Albuterol 2 – 4 puff

1 - 3 puff + Albuterol 2 - 4 puff

Dulera/Symbicort 2puffs QID

Dulera/Symbicort 3puffs QID

fluticasone

Daily ICS or ICS-

LABA +prn SABA

Daily ICS + prn

1-2puff qD – BID

if intermittent sx's

1-2puff qD – BID

if intermittent sx's

SABA

("recurrent

wheezing")

persistent

Mod-Severe

Mod-Severe

Persistent

Persistent

asthma

Mild

5 - 11

Years

Years

0 - 3

Years

4 - 11

Years

Years

12+

12+

No

Yes

SMART?

No

Yes

Yes

For URIs, cough, 2 – 8 puffs wheeze, SOB per dose

4 times a day





Neohaler"

inhalation powder

75 mca

indacaterol

Allergy & Asthma Network is a national nonprofit organization dedicated to ending needless death and suffering due to LONG-ACTING BETA₂-AGONIST BRONCHODILATORS relax tight muscles asthma, allergies and related conditions through outreach,













Symbicort®

budesonide and

80/4.5, 160/4.5 mcg





Diskus® 50 mcg salmeteral vinafoat inhalation nowd 123 AC



Striverdi® Respimat® 2.5 mcg olodaterol hydrochloride 123 C



THE CORTICOSTEROIDS reduce and prevent swelling of airway tissue; they do not relieve sudden symptoms of









era®

200/5 mcg



Wixela™ Inhub"

100/50, 250/50,

500/50 mcg

















AeroChamber®

Anoro® Ellipt 62.5/25 mca umeclidinium and







A minimally invasive procedure that uses mild heat to reduce airway smooth muscle, leading to fewer severe asthma flares, ER visits. and days lost from activities. www.htforasthma.com





250, 500 mcg roflumilas



BIOLOGICS target cells and pathways that cause airway inflammation; delivered by injection or IV

Cingair® reslizumab













2.5mg if <30kg 5mg if >30kg

Nebulized Bronchodilators





4 boxes (100 vials) per prescription





Oral Corticosteroids

Oral Steroids for Moderate/Severe Persistent Asthma 1mg/kg/day x3 – 10 days

Prednisolone (15mg/5ml)



Prednisolone (15mg/5ml)



<u>OraPred</u> (15mg/5ml)



w/ SABA or ICS-formoterol

PediaPred (5mg/5ml)



Prelone Syrup

4 times a day



Prednisone Tabs

(1, 2.5, 5, 10, 20, 50mg)





Learning Objectives

- 1. Asthma diagnosis
- 2. Asthma assessment questionnaire in asthma management
- 3. 2020 Asthma Guideline Updates: intermittent inhaled steroids and SMART therapy
- 4. Case-based learning

AG: Original HPI

- AG is a 5 year old boy who has had nearly nightly coughing x3 months, worse over the past 2-4 weeks, and disruptive to sleep at least every 2 wks. There have been frequent interval URIs, when cough is more intensive. Coughing paroxysms (20 times in a row).
- Allegra was too sedating w/o relief of the cough (presumed post nasal drip).
- 2 puffs of albuterol, hypoallergenic bedding, humidifier have not relieved the cough.
- Required prednisone x2 over the prior year for wheezing.
 - prednisone & albuterol q4 x48 hrs relieved sx's within 24 hrs
- The allergist is recommending Singulair.




Why might this patient have asthma?

- Cough x3 months duration (>1 month)
- Nocturnal cough that is disruptive to sleep
- URIs induce coughing
- Reduced cough with use of prednisone and albuterol simultaneously


AG Initial Visit: 10/20/20

Dulera 100 (2p QID), pred x3


What to do? days + f/u in 2-6 wks



AG f/u Visit: 11/4/20 What to do? Dulera 100 (2p QID), pred x7 days + f/u in 2-6 wks




AG f/u Visit: 11/14/20 What to do? Dulera 200 (2p QID)+ f/u in 2-



AG f/u Visit: 1/18/21 What to do?

Dulera 200 (2p BID) + f/u in 1-3 mos






JH: Original HPI

- JH is a 16 y.o. high school football player (300lb lineman) who presents with a history of asthma, including persistent cough x2 months, worse at night. JH also has SOB, a lot of coughing during football practice, and while running, particularly in the cold. Bronchitis x4, tx'd with antibiotics and prednisone.
- JH has also used a combination of albuterol HFA (2 puffs) and albuterol nebs (1 vial) up to 5 times per day.
- How could albuterol dosing have been improved?

Why might this patient have asthma?


- Cough x2 months duration (>1month)
- Cough is worse at night
- Exercise and cold weather induce coughing
- Improved symptoms with past use of prednisone

JH Initial Visit: 12/22/20 Dulera 100 (2p QID), pred x10 days + f/u in What to do? 2-6 wks



JH f/u Visit: 2/8/21

Dulera 200 (2p BID) or Dulera 100 What to do? (2p QID) + f/u in 2-6 wks



NC: Original HPI

NC is a 4 y.o. male with a history of respiratory infections with wheezing, resulting in hospitalization x2. He does have recurrent wheezing and chest congestion with URIs. He is well during the summer. The parents report no symptoms between illnesses and no symptoms during physical activity.

In the past, he has been treated with Budesonide nebs (0.25mg BID), prn URIs


Why might this patient have asthma?

Recurrent wheezing


URI-induced wheezing

NC Initial Visit: 1/21/21 Budesonide nebs 1mg BID x7 days + What to do? Albuterol QID, prn URI sx's. f/u in 1-3 mos

Common pattern for young children with URI-induced asthma



NC f/u Visit: 4/19/21 Continue tx: Budesonide 1mg BID x7 days + What to do? Albuterol QID, prn URI sx's. f/u in 3-6 mos



Additional Thoughts Beyond Asthma Care

Health care in the U.S. is consistently worse for ethnic/racial minorities

Racial bias (e.g., stereotypes) are a source of racial disparities in health care

Is empathy possible w/o relatability?

UNEQUAL

CONFRONTING RACIAL AND ETHNIC
DISPARITIES IN HEALTH CARE

Brian D. Smedley, Adrienne Y. Stith, and Alan R. Nelson, Editors


Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care

Board on Health Sciences Policy

OF THE NATIONAL ACADEMIES

THE NATIONAL ACADEMIES PRESS Washington, D.C. www.nap.edu

Racial Inequities in Asthma Care Despite Higher Levels of Asthma Morbidity in Black Patients



Adapted from EM Zoratti. AJRCCM 1998 Aug;158(2):371-7. Health service use by African Americans and Caucasians with asthma in a managed care setting

Akin-Imran A et al. Ethnic variation in asthma healthcare utilization and exacerbation: systematic review and meta-analysis. ERJ Open Res. 2023 May 2;9(3):00591-2022.

Oraka E et al. Racial and ethnic disparities in current asthma and emergency department visits: findings from the National Health Interview Survey, 2001-2010. J Asthma. 2013 Jun;50(5):488-96.




Background: Why Cultural Competency?

- Nearly half of the children in California are Hispanic and/or have a foreign-born parent.
- Currently one of three of families speak a language other than English
- ~50% of our children are from ethnic or racial "minority" groups
- One out of every 8 children in the United States lives in California



Better Asthma Care if Cultural Competency Present





Asthma Resources

NIH Asthma Guidelines

https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates

NIH Asthma Guidelines Digital Toolkit

https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates/digital-toolkit

GINA Asthma Guidelines

https://ginasthma.org/pocket-guide-for-asthma-management-and-prevention/

Asthma Surveys

https://www.uclahealth.org/mattel/pediatric-pulmonology/patient-forms

Thank You!

Sande Okelo, MD, PhD sokelo@mednet.ucla.edu

Division of Pediatric Pulmonology and Sleep Medicine UCLA Mattel Children's Hospital



FAQs

1. How often should a patient with well-controlled asthma be seen?

Answer: at least every 3 months.

2. There are so many asthma medication options—so what is a short-list of go-to asthma medications?

Answer: Two of the more commonly covered inhaled steroids are Flovent (44, 110, 220) and QVAR (40, 80).

- 3) When should a patient be referred to an asthma specialist? **Answers:** 1) patient request; 2) admitted for asthma; 3) asthma remains uncontrolled.
- 4) Can patients be treated with as needed controller medications? **Answer:** Yes. 1mg of budesonide nebulized BID x7 days, at the onset of each URI or Symbicort/Dulera (asthma symptoms <3 days/month): 2 puffs BID.

Q & A